Fig. 3.

Enforced expression of Lmo4 enhances CD8⁺ T cell antitumor immunity. a Experimental design investigating the effect of Lmo4 overexpression on the antitumor immune response of CD8⁺ T cells. b, c Tumor size (b) and survival curve (c) of B16_KVP tumor-bearing wild-type mice after transfer of either 3.5 × 10⁵ pmel-1 Thy1.1⁺ or Lmo4-Thy1.1⁺ CD8⁺ T cells into wild-type mice treated with gp100-vv and IL-2. d Representative flow cytometry plot depicting the gating strategy to assess the frequency of human T_SCM cells, defined as CD45RA⁺CD45R0^-CD62L⁺CCR7⁺CD95⁺TCF1⁺ cells. e Percentage of T_SCM cells in LMO4-Thy1.1 and Thy1.1 transduced CD8⁺ T cells after activation by TransAct and subsequent culture in IL-7 and IL-21 for 7 days (n = 5). f Experimental design investigating the effect of LMO4 overexpression on the antitumor immune response of human CD19-CAR-modified CD8⁺ T cells (n = 5 to 7 mice/group). g Percentage of human CD8⁺ T cells in the peripheral blood of NXG mice bearing NALM6-GL leukemia 7 days after adoptive transfer of LMO4-Thy1.1 or Thy1.1 CD19-CAR CD8⁺ T cells in conjunction with recombinant human IL-15. h In vivo bioluminescent imaging and i survival of NALM6-GL-bearing NXG mice treated as in (g). (*P < 0.05. g, unpaired one-tailed Student’s t-test, i, P = 0.0597 log-rank (Mantel–Cox) test). (a, f) was created with BioRender.com